Back to top

United Therapeutics Corp. (UTHR)

Read MoreHide Full Article

United Therapeutics Corp.'s (UTHR) second quarter earnings of $1.43 per share were well above the year-ago earnings of $1.19 and the Zacks Consensus Estimate of $1.12. Higher revenues led to the improvement in earnings. The company maintained its guidance for 2012.

We believe the company is well-positioned to gain share in the pulmonary arterial hypertension (PAH) market. Lead product Remodulin continues to look very strong in both the intravenous (IV) and subcutaneous (SC) forms. With the approval of Adcirca and Tyvaso, the company has a varied range of therapies available for the treatment of PAH.

We believe the company's PAH product portfolio will drive strong top-and bottom-line growth. We maintain our Outperform recommendation on United Therapeutics, which carries a Zacks #2 Rank (short-term Buy rating).

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

United Therapeutics Corporation (UTHR) - free report >>

More from Zacks Bull of the Day

You May Like